USA Compounding Pharmacies Market By 2023 to 2033: Future Opportunities and Challenges
The USA compounding pharmacies market is on an impressive growth trajectory, poised to reach a valuation of USD 11,099.0 million by 2023, according to the latest market analysis. This robust expansion is driven by the increasing demand for personalized medication solutions tailored to individual patient needs.
From 2023 to 2033, the sector is expected to sustain a strong compound annual growth rate (CAGR) of 7.8%, culminating in an estimated market value of approximately USD 23,430.35 million by the end of the forecast period. This growth is primarily attributed to the critical need to enhance medication safety and efficacy through customized pharmaceutical solutions.
Get your PDF Sample Report: https://www.futuremarketinsights.com/reports/sample/rep-us-978
Compounding pharmacies play a crucial role in the healthcare landscape by providing personalized pharmaceuticals that are not readily available in the mass market. These pharmacies address specific patient requirements, from customized dosages to alternative ingredients, thereby filling a significant gap in healthcare delivery.
Key Drivers of Market Growth:
- Rising Prevalence of Chronic Diseases: The increasing incidence of chronic conditions is fueling the demand for tailored treatment solutions.
- Need for Specialized Treatments: There is a growing need for customized medications for rare diseases and conditions.
- Medication Alternatives: The rising prevalence of allergies and intolerances drives demand for alternative medication solutions.
Market Highlights:
- The USA compounding pharmacies market grew at a CAGR of 5.2% from 2018 to 2022.
- The oral and topical medicine sectors are anticipated to dominate, with the sector's regional market share exceeding 60% in 2022.
- Hormone Replacement Therapy (HRT) saw an increase in market share, reaching 39% in 2022.
- Regular pharmacies accounted for over 27% of the market share in 2022.
Sabyasachi Ghosh, Associate Vice President at Future Market Insights (FMI), commented, “The market will see substantial growth during the projected period due to the rising prevalence of chronic illnesses like cancer and increased financing for compounding pharmacies in the USA.”
Competitive Landscape: Prominent players in the USA compounding pharmacies market include:
- Avella Specialty Pharmacy
- Central Admixture Pharmacy Services Inc.
- Hoye’s Pharmacy
- Vertisis Custom Pharmacy
- Smith Caldwell Drug Store
- Sixth Avenue Medical Pharmacy
- Cantrell Drug Company
- Clinigen Group
- Dougherty’s Pharmacy
- Fagron N.V.
Recent Developments:
- Adamis Pharmaceuticals Corporation announced in 2021 the sale of US Compounding Inc.'s assets for USD 15 million.
- Harrow revealed in 2023 that its subsidiary ImprimisRx will offer patent-pending compounded Atropine formulations.
- Nephron Pharmaceuticals Corporation launched a new syringe presentation in 2022 as part of its successful Nephron 503B Outsourcing Facility business.
Market Segmentation:
- By Product: Oral Medication (Solid, Liquid), Topical Medication, Injectable, Mouthwashes, Nasal, Ocular, Otic, Suppositories and Enemas.
- By Pharmacy Type: 503A Pharmacy, 503B Pharmacy.
- By Application: Adults, Pediatrics, Geriatrics, Veterinary.
- By Therapeutic Area: Hormone Replacement Therapy, Pain Management, Dermatology, Oncology, Hematology, Dental, Others.
Comments
Post a Comment